Abstract. although the B-cell translocation gene 1 (BTG1) plays an important role in apoptosis and negatively regulates cell proliferation, BTG1 expression in hepatocellular carcinoma (Hcc) has not been evaluated. in this study expression analysis of BTG1 was conducted to clarify the role of BTG1 in the initiation of Hcc carcinogenesis and progression. BTG1 mrna expression levels were determined for Hcc cell lines and 151 surgical specimen pairs using quantitative real-time reverse transcription polymerase chain reaction (rt-qPcr) assay. the mutational and methylation status of Hcc cell lines were analyzed via high resolution melting (HrM) analysis and direct sequencing analysis to elucidate the regulatory mechanisms of BTG1 expression. the expression and distribution of the BTG1 protein in liver tissues were evaluated using immunohistochemistry (iHc). Decreased expression of BTG1 mRNA was confirmed in the majority of HCC cell lines (89%) and clinical HCC tissues (85%) compared with non-cancerous liver tissues. Mutations or promoter hypermethylation were not identified in Hcc cell lines. BTG1 mrna expression levels were not influenced by background liver status. The pattern of BTG1 protein expression was consistent with that of BTG1 mrna. Downregulation of BTG1 mrna in Hcc was significantly associated with shorter disease-specific and recurrence-free survival rates. Multivariate analysis of disease-specific survival rates identified BTG1 mrna downregulation as an independent prognostic factor for HCC (hazard ratio 2.12, 95% confidence interval 1.12-4.04, P=0.022). our results indicate that altered BTG1 expression might affect hepatocarcinogenesis and may represent a novel biomarker for HCC carcinogenesis and progression.
Introduction
Hepatocellular carcinoma (Hcc) is the sixth most common cancer and the third most common cause of cancer-related mortality worldwide. Hcc is also the leading cause of death among cirrhotic patients (1, 2) . Most Hcc cases occur in sub-Saharan africa and eastern asia; however, the incidence rate has been increasing in some developed countries, including japan, the united Kingdom, france, and the united States (3, 4) . all patients diagnosed with advanced stages of the disease exhibit very limited survival, and to date, only treatment with the multikinase inhibitor sorafenib has improved survival rates for these patients (5, 6) .
in contrast to most other solid tumors, the underlying cirrhotic liver disease found in Hcc patients greatly complicates the tumor-related prognosis, which presents a unique situation in which accurate prognostic prediction is a relevant and unmet need (2, 7, 8) . Chronic inflammation induced by chronic viral hepatitis, alcohol consumption or aflatoxin and subsequent hepatocyte regeneration are underlying causes of HCC (9) . Continuous inflammation occasionally damages DNA in the hepatocytes of the regenerating liver and thereby increases the chance of developing a gene alteration that may lead to carcinogenesis. The molecular profiling of HCC has led to a better understanding of the physiopathology of this neoplasm and has allowed the development of novel therapeutic approaches (e.g., molecular targeted therapies) for tumors previously considered to be therapy-refractory (10, 11) . integrative analyses of genetic and epigenetic information obtained for the tumor and the surrounding tissue should be used to identify novel biomarkers and therapeutic targets in Hcc to improve existing treatment algorithms and eventually design a more personalized therapy for this devastating disease (12, 13) .
We have identified several HCC-related genes by expression and epigenetic analyses (14, 15) . from the exhaustive expression analysis obtained via our microarray data, the (16) (17) (18) . BTG1 is constitutively expressed in quiescent cells, and its expression is downregulated as cells enter the growth cycle (19, 20) . Experiments in which gene expression was induced showed that BTG1 is a Bcl-2-regulated mediator of apoptosis and that it negatively regulates cell proliferation in breast and ovarian cancer (20, 21) . However, the role of BTG1 in gastroenterological malignancies including Hcc remains unclear.
The aims of this study were to evaluate the clinical significance of BTG1 expression, examine the regulatory factors involved in BTG1 transcription, clarify the roles of BTG1 in hepatocarcinogenesis and its subsequent progression, and propose a potential diagnostic and therapeutic molecular target for Hcc.
Materials and methods
Ethics. this study conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki -Ethical Principles for Medical Research Involving Human Subjects and has been approved by the institutional review Board of Nagoya University, Aichi, Japan (no. 2013-0295). Written informed consent for usage of clinical samples and data, as required by the institutional review Board, was obtained from all patients.
Sample collection. nine Hcc cell lines (Hep3B, Hepg2, HLE, HLF, HuH1, HuH2, HuH7, PLC/PRF/5 and SK-Hep1) were obtained from the american type culture collection (Manassas, Va, uSa). Primary Hcc tissues and corresponding non-cancerous tissues were collected from 151 consecutive patients undergoing liver resection for Hcc at nagoya University Hospital between January, 1998 and January, 2012. treatment after recurrence generally included the following options: surgery, radiofrequency ablation, transcatheter arterial chemoembolization, and chemotherapy according to tumor status and liver function.
Tissue samples were collected, immediately flash frozen in liquid nitrogen and stored at -80̊C until RNA extraction (28 days on average) was performed. tumor samples ~5 mm 2 in size that did not contain a necrotic component and were confirmed to contain >80% tumor cells by definition were used for rna extraction. corresponding non-cancerous liver tissue samples were collected >2 cm away from the edge of the tumor, were obtained from the same patient and did not contain any regenerative or dysplastic nodules.
Microarray procedure. Sample collection, rna extraction, and affymetrix Hg-u133a and Hg-u133B genechip (affymetrix, inc., Santa clara, ca, uSa) gene expression arrays were performed as previously described (22) (23) (24) .
Quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR). the BTG1 mrna expression levels were analyzed by rt-qPcr. total rna (10 µg per sample) was isolated and used to generate complementary Dna. the primer sequences used in this study are listed in Table Ⅰ . rt-qPcr was performed on nine Hcc cell lines and 151 pairs of clinical samples with a SyBr-green Pcr core reagents kit (Perkin-Elmer/Applied Biosystems, Inc., Foster City, CA, uSa) and included no-template samples as a negative control. real-time detection of the SyBr-green emission intensity was conducted with an aBi SteponePlus real-time Pcr system (Perkin-Elmer/Applied Biosystems, Inc.). The expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was quantified in each sample for standardization. for cell lines, biological replicates were tested in triplicate. technical replicates were performed in triplicate for both cell lines and Hcc tissues. the expression levels for each sample are shown as the BTG1 value divided by the GAPDH value. BTG1 mrna expression was considered to be downregulated in tumor tissues when its level was <40% of the level in the corresponding non-cancerous tissues.
Mutational analysis. the BTG1 gene consists of two exons. Mutational surveillance of Hcc cell lines was performed in exon 1 and 2 of the BTG1 gene by high resolution melting (HRM) analysis. HRM is known to be a reliable and concise technique for the detection of genetic alterations (25) (26) (27) . genomic Dna obtained from Hcc cell lines was amplified with specific primer pairs according to the manufacturer's instructions (life technologies, carlsbad, ca, uSa). all samples were tested in triplicate. eight wells of each Pcr plate were allocated to wild-type control Dna, and one well contained a non-template control to validate the Pcr. HrM was conducted using a SteponePlus instrument (life technologies) with a melting temperature range set between 60 and 98̊C. Scanning data were analyzed by HRM software v3.0.1 (life technologies). the primers used for mutational analysis are listed in Table Ⅰ .
Bisulfite sequencing analysis. the BTG1 gene contains a cpg island near the promoter region; thus, we hypothesized that aberrant methylation is responsible for regulating BTG1 transcription in HCC. Genomic bisulfite-treated DNA from HCC cell lines was sequenced to ascertain the levels of Dna methylation. The bisulfite treatment and sequencing procedures were performed as previously reported (28, 29) .
Immunohistochemistry (IHC)
. iHc was performed to investigate BTG1 protein localization in 48 representative sections of well-preserved Hcc tissue as described previously (30) . Sections were incubated for 1 h at room temperature with a rabbit antibody directed against BTG1 (Pa5-25035; thermo Fisher Scientific, Inc., Rockford, IL, USA) diluted 1:100 in antibody Diluent (Dako, Carpinteria, CA, USA) and then developed for 2 min using liquid 3,3'-diaminobenzidine as the substrate (Nichirei Corp., Tokyo, Japan). The staining patterns were compared between Hcc tissue and the corresponding non-cancerous tissue. the intensity of BTG1 protein expression was graded depending on the percentage of stained cells as follows: no staining, minimal (<30%); focal (30-70%); and diffuse (>70%) (31) . To avoid subjectivity, specimens were randomized and coded before analysis by two independent observers blinded to the status of the samples. each observer evaluated all the specimens at least twice within a given time interval to minimize intra-observer variation.
Statistical analysis. the values between the two groups were analyzed using the Mann-Whitney u test. the χ 2 test was used to analyze the association between the expression status of BTG1 and clinicopathological parameters. the strength of the correlation between two variables was assessed by Spearman's rank correlation coefficient. Disease-specific and -free survival rates were calculated using the Kaplan-Meier method, and the difference in survival curves was analyzed using the log-rank test. We performed multivariable regression analysis to detect prognostic factors using the cox proportional hazards model, and variables with P<0.05 were entered into the final model. all statistical analysis was performed using jMP 10 software (SaS institute, inc., cary, nc, uSa). P<0.05 was considered statistically significant.
Results
Patient characteristics. the age of the 151 patients ranged from 34-84 years (median 64 years), and the male-to-female ratio was 126:25. thirty-seven patients presented with hepatitis B infections, and 84 patients presented with hepatitis c infections. in terms of the non-cancerous liver samples, the number of patients with normal liver, chronic hepatitis, and cirrhosis were 10, 87, and 54, respectively. When classified according to the 7th edition of the UICC classification, 84, 39 and 18 patients were in stages Ⅰ, Ⅱ and Ⅲ, respectively.
Expression array. gene expression that was reduced further in tumor tissues than in the corresponding non-cancerous tissues was used to identify new candidate tumor suppressors in Hcc. BTG1 expression was reduced in Hcc compared with normal tissue, with a log 2 ratio of -1.6 and -1.5 (Table Ⅱ) .
BTG1 mRNA expression and regulatory mechanisms in HCC cell lines. Decreases in BTG1 mRNA were confirmed in eight (89%) of the nine HCC cell lines compared with the median expression level in non-cancerous liver tissues; these results demonstrate the heterogeneity of BTG1 expression in Hcc cell lines (fig. 1a) . no mutations were detected by the HrM analysis of BTG1 exons 1 and 2 (fig. 1B) . Direct nucleotide sequence analysis of bisulfite-treated GC cell lines showed absence of hypermethylation of BTG1 promoter region in all gc cell lines ( fig. 1c) . Expression status of BTG1 in 151 clinical HCC samples. the BTG1 mrna expression levels of non-cancerous tissue samples were categorized pathologically into normal liver (n=10), chronic hepatitis (n=87), and cirrhosis (n=58). upon evaluation of these samples, no significant differences were found, suggesting that the expression of BTG1 mrna in non-cancerous liver was not affected by background liver fibrosis (Fig. 1D) . In 129 (85%) of 151 patients, the expression level of BTG1 mrna was lower in the Hcc tissues than in the corresponding normal tissues. The HCC tissues exhibited significantly lower expression levels of BTG1 mrna than the corresponding normal tissues (P<0.001, fig. 1D ). expression patterns of the BTG1 protein were evaluated by iHc. representative cases with downregulated BTG1 mrna expression in Hcc tissues exhibited reduced expression of the BTG1 protein in the cytoplasm of the cancerous tissues compared with the adjacent non-cancerous tissues ( fig. 2a) . overall, the staining intensity (shown in fig. 2B ) of the BTG1 protein in 48 patients was consistent with the rt-qPcr data ( fig. 2c) . There were no significant differences in the BTG1 mrna expression levels observed in non-cancerous tissues among the three patient groups categorized by background liver status. HCC tissues showed a lower mean expression of BTG1 mrna than the corresponding normal tissues. NS, not significant. tissues. the downregulation of BTG1 mrna in the Hcc samples was significantly associated with male gender, protein induced by vitamin K antagonists (PIVKA) Ⅱ >40 mAU/ml, tumor size ≥3 cm, tumor differentiation (poorly to moderately differentiated), serosal infiltration, vascular invasion, advanced uicc stage, and extra-hepatic recurrence (Table Ⅲ) . The BTG1 mrna expression levels in Hcc tissues were inversely correlated with preoperative PIVKA Ⅱ levels ( fig. 3a) . Patients exhibiting a downregulation of BTG1 mrna expression in the HCC samples had a significantly shorter disease-specific survival rate than the other patients (2-year survival rates, 67 and 82%, respectively, Fig. 3B ). Multivariate analysis identified the downregulation of BTG1 mrna as an independent prognostic factor for Hcc (hazard ratio 2.12, 95% confidence interval 1.12-4.04, P=0.022, Table Ⅳ ). in terms of recurrence-free survival rates, patients with a substantial downregulation of BTG1 mrna in the Hcc samples had significantly earlier recurrence rates after surgery than the other patients (2-year recurrence-free survival rates: 39 and 65%, respectively, P=0.032, Fig. 3C ).
Discussion
Btg is a nuclear protein that is imported into the nucleus through a nuclear localization signal; its nucleocytoplasmic translocation depends on the stage of cell growth and is mediated by a nuclear export signal (32) (33) (34) . accordingly, the Btg family, which is thought to play an intimate role in the proliferation of cancer cells, has attracted attention in recent years (34, 35) . BTG1 has been shown to enhance homeobox B9-mediated transcription in transfected cells and mediate its antiproliferative function. as shown by Dna fragmentation and nuclear condensation, BTG1 localizes to specific macrophage-rich regions in human lesions and apoptotic cells (36) . BTG1 mrna is abundantly expressed in quiescent endothelial cells and is decreased upon the addition of angiogenic growth factors (19) .
in this study, the expression status and regulatory mechanisms of BTG1 were investigated in Hcc. following the confirmation that BTG1 mRNA expression is remarkably suppressed in most Hcc cell lines, the somatic mutation and Dna methylation statuses were evaluated as possible mechanisms of suppression. no mutations were detected in any of the HCC cell lines examined by the HRM. In addition, bisulfite sequencing showed absence of hypermethylation in the BTG1 promoter in all GC cell lines. These findings were consistent with those in acute lymphoblastic leukemia (37) , and further study will be needed to elucidate the alterative underlying molecular pathway suppressing BTG1 transcription.
interestingly, the expression analysis of clinical samples demonstrated important clinical implications for the expression of BTG1. BTG1 was downregulated in most Hcc tissues, and the strong suppression of BTG1 was an independent prognostic factor associated with early recurrence. these results indicate that BTG1 is a putative tumor suppressor gene that affects both carcinogenesis and the subsequent progression of Hcc. the potential use of BTG1 expression as a prognostic biomarker is supported by the finding that BTG1 expression in Hcc tissues was inversely correlated with the serum levels of PIVKA Ⅱ, an important HCC tumor marker.
in clinical practice, aggressive pre-and post-operative systemic therapy could be considered for patients exhibiting strong downregulation of BTG1 identified in biopsies or surgical specimens in anticipation of early recurrence and an adverse prognosis. BTG1 interacts with and regulates the activity of protein arginine methyl transferase (PRMT)1 (38, 39) . Members of this enzyme family, including PrMt1, are considered global regulators of gene expression that act as transcriptional coregulators of the arginine methylation of histone tails and are critical regulators of transcription (40) . Based on our results, the forced expression or artificial modification of interacting molecules (including PRMT1) of BTG1 may be used as novel therapeutic approaches for the treatment of Hcc. for future consideration, external validation is necessary, and functional analysis of the BTG1 gene could help to further clarify the role that BTG1 plays in the progression of Hcc. in summary, the reduced expression of BTG1 mrna was associated with early recurrence rates and subsequent poor prognoses in patients with Hcc. our results indicate that altered BTG1 expression might affect hepatocarcinogenesis and may represent a novel biomarker for the initiation of carcinogenesis and the progression of Hcc.
